Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. With molecule biology and immune techniques, we have mastered expertise in TCR-T preclinical in vivo test. Our platform can further support rapid and precise assay. Our TCR-T preclinical in vivo test services, which is fast, reliable, and affordable, can be tailor-designed to meet your specific needs.
Adoptive T-cell therapy involves the isolation, expansion and reinfusion of T lymphocytes with a defined specificity and function as a means of eradicating cancer. Creative Biolabs’ advanced platform of TCR-T preclinical in vivo test provides our clients various techniques to detect different aspects of TCR-T index, such as T cell trafficking test, T cell persistence test, safe/toxicity evaluation.
Creative Biolabs’ TCR-T preclinical in vivo test services include but not limited to:
To ensure further preclinical development of TCR therapy, it is necessary to construct animal models to test various indexes in vivo. A series of stringent criteria are applied to quality control of xenograft models in order to guarantee reliability. We design assay protocols with customers and select the most appropriate methods to advance your TCR-T cell therapy development programs.
Naïve T cells are migratory cells that continuously recirculate between blood and lymphoid tissues. Antigen-specific stimulation of T cells within the lymph nodes reprograms the trafficking properties of T cells by inducing a specific set of adhesion molecules and chemokine receptors on their surface which allow these activated and effector T cells to effectively and specifically home to extralymphoid organs. The observations of organ-specific homing of T cells initiate the development of therapeutic strategies targeting adhesion receptors for organ-specific inhibition of chronic inflammation. As most adhesion receptors have additional immune functions besides mediating leukocyte trafficking, these drugs may have additional immunomodulatory effects.
T cell persistence is likely to promote long-term anti-tumor effects after adoptive T cell transfer. However, a major obstacle associated with current TCRs immunotherapy is that the limited replicative lifespan of TCRs prohibits the long-term persistence and expansion of these cells in vivo, potentially hindering the long-term therapeutic effects of TCR.
Recent clinical trials have produced many encouraging data for TCR-T cell therapy against various types of cancers, which inspires further development of TCR-T cell therapies. Preclinical in vivo therapeutic efficacy test of TCR-T cells in animal models provides valuable information for their late clinical application.
Although we are all aware of the benefits of the immune cell defense against diseases factors, it is also true that in some cases, severe acute and chronic damage can be inflicted on the host by these same cells. The concept behind adoptive T-cell transfer is to greatly enhance the T cell repertoire against cancer by administering tumor-reactive T cells expanded and activated in vitro. So it should be no surprise that toxicities from these cells could also be enhanced.
From the foremost project design to the final data interpretation, Creative Biolabs implements strict inspections and validations on each and every step. We are able to conduct projects in standardized procedures that conform to the GLP (FDA/OECD) regulations, which are essential for the IND application.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE